How has been the historical performance of Sotac Pharma.?

Answer:The historical performance of Sotac Pharma shows a fluctuating trend in net sales and profitability over the years leading up to March 2025.

Breakdown:
Sotac Pharma's net sales peaked at 103.83 Cr in March 2024 but decreased to 96.99 Cr in March 2025, following a steady increase from 28.60 Cr in March 2020 to 77.48 Cr in March 2023. The total operating income mirrored this trend, reaching 96.99 Cr in March 2025. The company's total expenditure, excluding depreciation, was 83.34 Cr in March 2025, down from 95.32 Cr in March 2024, indicating improved cost management. Operating profit (PBDIT) saw significant growth, rising to 17.55 Cr in March 2025 from just 1.56 Cr in March 2021, while profit before tax also improved to 11.12 Cr in March 2025, compared to a loss of 2.06 Cr in March 2021. The profit after tax reached 9.28 Cr in March 2025, a substantial increase from 2.29 Cr in March 2023 and a loss of 2.37 Cr in March 2021. The earnings per share (EPS) also reflected this positive trend, increasing to 7.27 in March 2025 from -10.3 in March 2021. On the balance sheet, total liabilities increased to 103.90 Cr in March 2024 from 73.64 Cr in March 2023, while total assets rose to the same level, indicating a balanced growth in the company’s financial position. Cash flow from operating activities was negative at -16.00 Cr in March 2024, but financing activities provided a net inflow of 29.00 Cr, showcasing reliance on external financing. Overall, Sotac Pharma's performance indicates a recovery and growth trajectory in profitability and operational efficiency despite some fluctuations in sales and cash flow.